BTOG 2019 | DDR proteins emerging as biomarkers and targets in lung cancer: the case of hSSB1
Kenneth O'Byrne
Presenting an array of work from his group in Brisbane on DNA damage repair proteins that are emerging as biomarkers and targets in lung cancer, Ken O’Byrne, MD, of the Princess Alexandra Hospital, Brisbane, Queensland, Australia, spoke to us about the context and application of this research. Prof. O’Byrne highlights hSSB1, discovered by his research partner Prof. Derek Richard, a highly conserved and important protein in the DNA damage repair process, and goes on to discuss the upcoming translation of this work into a clinical trial. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland.
Similar topics
Related videos

Accelerate, Coordinate, Evaluate (ACE) cancer care: the CRUK programme streamlining the care pathway
Sara Hiom

Lung cancer screening in the UK: CRUK, UK NSC, Public Health England & NHS England
Sara Hiom

The Recovery Package in lung cancer
Josie Roberts

Single-port VATS for NSCLC: outcomes related to smoking status
John Edwards

Psychological impact of lung cancer screening
Mamta Ruparel
et al.
More from Kenneth O'Byrne